Search research articles
Contact Us
Filters
Showing results (141-150 of 149) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 149 results.
Bioconjugate Chemistry
|
January 20, 2005
Synthesis of new bivalent peptides for applications in the Affinity Enhancement System
L Morandeau, E Benoist, A Loussouarn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial
J P Vuillez, F Kraeber-Bodéré, D Moro, et al.
European Journal of Nuclear Medicine
|
January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragments
A Chetanneau, R P Baum, P A Lehur, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 1998
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody
J Barbet, P Peltier, S Bardet, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 2, 2004
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer
E Mirallié, J P Vuillez, S Bardet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1996
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer
M Bardiès, S Bardet, A Faivre-Chauvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial
F Kraeber-Bodéré, S Bardet, C A Hoefnagel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma
O Couturier, A Faivre-Chauvet, I V Filippovich, et al.
Bulletin Du Cancer
|
December 23, 2000
[Immunotargeting of tumors: state of the art and prospects in 2000]
A Pèlegrin, F Xavier, J Barbet, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 149) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 149 results.
Bioconjugate Chemistry
|
January 20, 2005
Synthesis of new bivalent peptides for applications in the Affinity Enhancement System
L Morandeau, E Benoist, A Loussouarn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial
J P Vuillez, F Kraeber-Bodéré, D Moro, et al.
European Journal of Nuclear Medicine
|
January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragments
A Chetanneau, R P Baum, P A Lehur, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 1998
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody
J Barbet, P Peltier, S Bardet, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 2, 2004
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer
E Mirallié, J P Vuillez, S Bardet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1996
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer
M Bardiès, S Bardet, A Faivre-Chauvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial
F Kraeber-Bodéré, S Bardet, C A Hoefnagel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma
O Couturier, A Faivre-Chauvet, I V Filippovich, et al.
Bulletin Du Cancer
|
December 23, 2000
[Immunotargeting of tumors: state of the art and prospects in 2000]
A Pèlegrin, F Xavier, J Barbet, et al.
Page
of 15